Muhydeen Damilola Badru

Why Cancer Immunotherapy Fails?: Mechanisms of Resistance and Emerging Reversal Strategies

Muhydeen Damilola Badru, Tobi Ayomide Lawal, Udeichi Nnenna Chidimma, Mayowa Josiah Badmus, Francis Esther Ene, Daniel Chinaza Anyirionye, Naomi Ngozichukwuka Ajoniloju, Adegbesan Abiodun Christopher & Comfort Mary Afolabi · Journal of Cancer and Tumor International · 2025

Cancer immunotherapy has revolutionized the field of oncology by enabling the immune system to target and destroy cancer cells. Therapies such as immune checkpoint inhibitors, including PD-1/PD-L1 and CTLA-4 blockade, and chimeric antigen receptor T (CAR-T) cells have shown unpre...

Open access Research Article 10.9734/jcti/2025/v15i3306

Decoding Tumor Heterogeneity through Multi Omics: Insights into Cancer Evolution, Microenvironment and Therapy Resistance

Paul-Miki Raluchukwu Ibekwe, Elizabeth Anuoluwa Akintayo, Cecilia Ndiuwem Okuku, Ismaila Muhammed, Fuhad Mayowa Jeje, Okun, Oseghale, Kemiki Olalekan Ademola, Muhydeen Damilola Badru & Lydia Amarachi Onwuemelem · Journal of Cancer and Tumor International · 2025

Background: The existence of genetically, epigenetically, and phenotypically distinct cell populations inside and between tumors is known as tumor heterogeneity, and it is one of the main barriers to effective cancer treatment. This intricacy affects the likelihood of metastasis,...

Open access Research Article 10.9734/jcti/2025/v15i3305